Heartflow Inc. recently submitted its S-1 filing to the SEC, adding to a growing list of medtech companies pursuing public offerings in 2025, signaling robust investor interest in the sector. Simultaneously, Thermo Fisher Scientific is acquiring Sanofi’s Ridgefield, NJ sterile manufacturing site and plans to expand U.S. CDMO capacity to meet increasing industry demand. These developments highlight ongoing infrastructure investments and capital market activity as the medtech field continues to evolve and expand.